United States securities and exchange commission logo





                              September 15, 2021

       Ian McDonald
       Chief Executive Officer and Director
       Bright Minds Biosciences Inc.
       Suite 1500, 1055 West Georgia Street, PO Box 11117
       Vancouver, British Columbia, Canada, V6E 4N7

                                                        Re: Bright Minds
Biosciences Inc.
                                                            Amendment No. 3 to
Registration Statement on Form 20-FR12G
                                                            Filed August 27,
2021
                                                            File No. 000-56296

       Dear Mr. McDonald:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

            After reviewing your response and any amendment you may file in
response to these
       comments, we may have additional comments.

       Amendment No. 3 to Registration Statement on Form 20-F

       Principal Products, page 19

   1.                                                   Please revise the study
outcome descriptions in the table presenting your preclinical trials
                                                        to disclose your
objective observations from the trials without concluding that the product
                                                        candidate was effective
or had an impact on the observed results. Any conclusions
                                                        regarding efficacy are
within the sole authority of the FDA. For example, you may
                                                        indicate that test
subjects treated with your product candidate experienced 47% fewer
                                                        binge eating episodes
than those participants that were not treated with your product
                                                        candidate. However,
stating that the product candidate suppressed the number of binge
                                                        eating episodes by 47%
presents an inappropriate statement about the efficacy of the
                                                        product candidate.
Please review the description of the study outcomes and revise the
                                                        descriptions of the
outcome accordingly.
 Ian McDonald
Bright Minds Biosciences Inc.
September 15, 2021
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       You may contact Lynn Dicker at 202-551-3616 or Eric Atallah at
202-551-3663 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jordan Nimitz at 202-551-6001 or Suzanne Hayes at 202-551-3675 with any
other
questions.



                                                          Sincerely,
FirstName LastNameIan McDonald
                                                          Division of
Corporation Finance
Comapany NameBright Minds Biosciences Inc.
                                                          Office of Life
Sciences
September 15, 2021 Page 2
cc:       Michael Shannon, Esq.
FirstName LastName